कंपनी का अवलोकन
XOMA Royalty Corporation functions as a biotech royalty aggregator, securing economic rights to future milestone payments and royalties associated with both commercial products and pre-commercial therapeutic candidates across the United States, Switzerland, the Asia Pacific region, and Australia. The enterprise operates within the healthcare sector and specifically within the biotechnology industry, positioning itself to generate income streams from third-party drug development without requiring capital expenditure on manufacturing or clinical trials. As of the latest available data, the company reports a trailing twelve-month revenue of $52.15M and employs a workforce of 14 individuals. Although the market capitalization is listed as unavailable in current filings, the combination of significant annual revenue and a substantial cash reserve of $83.29M indicates a robust operational scale for an entity with a minimal headcount. This financial structure suggests the company possesses a mature revenue model capable of sustaining operations while leveraging its intellectual property portfolio to generate returns independent of traditional biotech capital intensity.
वित्तीय स्वास्थ्य
The company recorded a revenue of $52.15M for the trailing twelve months, generating a net income of $18.52M and an EBITDA of $14.36M. The substantial gap between the $52.15M revenue and the $18.52M net income reveals a highly efficient cost structure where operating expenses and tax burdens consume approximately 64.8% of top-line sales, leaving a robust bottom line. However, the free cash flow stands at -$14,235,375, indicating that despite strong accounting profitability, the company is currently consuming cash, likely due to strategic acquisitions, royalty purchases, or operational capital expenditures that exceed cash generation from current sales. This negative cash flow position necessitates careful management of liquidity, given the company holds $83.29M in cash against total debt obligations of $131.56M. The balance sheet reflects a leveraged stance, evidenced by a debt-to-equity ratio of 126.54, which implies the company relies significantly on external financing rather than retained earnings for its asset base. Nevertheless, the current ratio of 3.37 demonstrates exceptional short-term liquidity, suggesting the firm has more than three times the current assets required to settle its immediate liabilities without distress. Furthermore, the return on equity of 34.1% and return on assets of 2.9% indicate that management is highly effective at generating equity returns, though the low asset return reflects the asset-light nature of the royalty aggregation business where high-value intellectual property replaces heavy physical assets.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 25.98, while the forward P/E is unavailable, making a direct comparison to gauge future earnings trajectory impossible with current data. The price-to-book ratio stands at 3.68, which indicates that the market values the company at a significant premium over its net book value, likely reflecting the high intangible value of its royalty portfolio that is not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio, which is unavailable, and the EV/EBITDA of 26.33, provide context for the company's valuation relative to its operational cash earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $26.40 and a 52-week low of $24.61, meaning the current trading price sits within a relatively narrow range of approximately 1.79 dollars or about 6.8% below the annual peak. The beta value of 0.68 suggests that the stock exhibits lower volatility relative to the broader market, moving less dramatically than the overall index and offering a degree of stability for risk-averse portfolios seeking exposure to the biotech sector.
Growth & Income
Revenue growth for the trailing twelve months is 57.9%, whereas earnings growth is listed as unavailable, preventing a direct year-over-year comparison of profitability expansion versus top-line expansion. In the absence of specific earnings growth data to contrast with revenue, the high revenue growth rate of 57.9% implies a rapid expansion in the portfolio's value or the monetization of new royalty agreements. The company offers a dividend yield of 8.1%, but the payout ratio is unavailable, which limits the ability to assess the sustainability of the dividend against current earnings per share. Despite the lack of a calculated payout ratio, the high dividend yield relative to the available earnings suggests the company may be paying out a significant portion of its income, potentially leveraging its cash reserves to maintain this yield. The overall growth and income profile is characterized by substantial top-line expansion and a high current yield, though the negative free cash flow and high debt levels introduce complexity regarding the long-term sustainability of both dividend payments and revenue growth rates without additional financing or operational efficiency improvements.